Cite

    Kaur, P. et al. (2017). A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Annals of the rheumatic diseases. 76 (3), pp. 526-533. [Online].